AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)

NCT07437456 | Not Yet Recruiting

• 1 other identifier: AF-CARD
• Study Type: observational
• Target: 3,500
• Locations: 1 country
• Sites: 1

Brief Summary

Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.

Conditions

Atrial Fibrillation (AF)

Keywords

Atrial Fibrillation; Anticoagulant Therapy; Thromboembolic Complications

Outcome Measures

Primary Outcomes (1)

• Cumulative incidence of thromboembolic complications

  To assess the cumulative incidence of atrial fibrillation-related thromboembolic complications (including transient ischaemic attack, ischaemic stroke, and systemic thromboembolism) in patients with initially low risk over the follow-up period.

  6, 12, 18, 24, 30, 36 month

Secondary Outcomes (13)

• Number of Atrial Fibrillation Paroxysms During the Follow-up Period

  6, 12, 18, 24, 30, 36 month

• Rate of Hospitalizations Due to Atrial Fibrillation Paroxysm During the Follow-up Period

  6, 12, 18, 24, 30, 36 months

• Rate of Catheter Ablation of Pulmonary Vein Ostia During the Follow-up Period

  6, 12, 18, 24, 30, 36 months

• Complications of Anticoagulant Therapy

  6, 12, 18, 24, 30, 36 months

• Proportion of Patients Who Switched from Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) to Oral Anticoagulants During the Follow-up Period

  6, 12, 18, 24, 30, 36 months

Study Arms (2)

Retrospective branch

The retrospective cohort will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the study inclusion criteria at the time of that visit.

Prospective branch

All patients aged 18 to 64 years at the time of data registration, with a specialist-confirmed diagnosis of atrial fibrillation and a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening.

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Anonymized male and female patients aged 18 to 64 years suffering from atrial fibrillation confirmed by a specialist, with a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.

You may qualify if:

• Male or female patients aged 18 to 64 years at the time of data registration;
• Presence of a specialist-confirmed diagnosis of atrial fibrillation;
• CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
• Age under 18 years;
• Age over 64 years;
• CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women;
• Inability to undergo screening examination and follow-up;
• Organ or tissue transplantation less than 5 years prior to study enrollment;
• Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment;
• Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake.
• Prospective Part
• Male or female patients aged 18 to 64 years at the time of data registration;
• Presence of a specialist-confirmed diagnosis of atrial fibrillation;
• CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening.
• Age under 18 years;

You may not qualify if:

• Patient withdrawal of consent for further participation in the study;
• Identification of factors precluding further patient participation in the study (at the physician's discretion).

Sponsors & Collaborators

• Eurasian Association of Therapists: lead

Study Sites (1)

Eurasian Association of Therapists

Moscow, Russia

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Alexander Arutyunov, professor

  Eurasian Association of Therapists

  STUDY CHAIR

Central Study Contacts

Dmitrii Evdokimov, PhD

CONTACT

+79112510942; d.evdokimov@euat.ru

Alexander Vaskin

CONTACT

+7 495 708-42-23; avaskin@euat.ru

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 22, 2026
• First Posted: February 27, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): January 1, 2029
• Last Updated: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

RU (1)